The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda.
Lawrence Lucchino was an American lawyer and Major League Baseball executive. He served as president of the Baltimore Orioles, president and chief executive officer (CEO) of the San Diego Padres, and president and CEO of the Boston Red Sox. He was also chairman of the Worcester Red Sox, the Triple-A affiliate of the Boston Red Sox; chairman of The Jimmy Fund, the philanthropic arm of the Dana–Farber Cancer Institute; and president and CEO emeritus of Fenway Sports Group, the parent company of the Boston Red Sox and Liverpool F.C. Lucchino played college basketball for the Princeton Tigers.
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.
Robert Samuel Langer Jr. FREng is an American biotechnologist, businessman, chemical engineer, chemist, and inventor. He is one of the nine Institute Professors at the Massachusetts Institute of Technology.
The Harvard–MIT Program in Health Sciences and Technology, or HST, is one of the oldest and largest biomedical engineering and physician-scientist training programs in the United States. It was founded in 1970 and is the longest-standing collaboration between Harvard University and the Massachusetts Institute of Technology (MIT). Within the program, graduate and medical students are registered with both MIT and Harvard and may work with faculty and affiliated faculty members from both communities. HST is a part of MIT's Institute for Medical Engineering and Science and forms the London Society at Harvard Medical School.
Richard Rox Anderson, FAAD, is a Boston-based dermatologist and entrepreneur.
Remyelination is the process of propagating oligodendrocyte precursor cells to form oligodendrocytes to create new myelin sheaths on demyelinated axons in the Central nervous system (CNS). This is a process naturally regulated in the body and tends to be very efficient in a healthy CNS. The process creates a thinner myelin sheath than normal, but it helps to protect the axon from further damage, from overall degeneration, and proves to increase conductance once again. The processes underlying remyelination are under investigation in the hope of finding treatments for demyelinating diseases, such as multiple sclerosis.
David A. Edwards is an American biomedical engineer, and the founder of Sensory Cloud. He was the Gordon McKay Professor of the Practice of Biomedical Engineering at Harvard University.
William F. Pounds (1928–2023) was an American academic who served as the dean of the MIT Sloan School of Management from 1966 to 1980 and later as a professor emeritus at the MIT Sloan School of Management. He was chief financial adviser to the Rockefeller family and an executive in many of their holdings.
Dietrich A. Stephan is an American human geneticist and entrepreneur who works in personalized medicine. Stephan is currently CEO of NeuBase Therapeutics and a General Partner in Cyto Ventures. Before NeuBase, Stephan was CEO of LifeX and Chairman and Professor of Human Genetics at the University of Pittsburgh. Prior, he was founding Chairman of the Neurogenomics Division at the Translational Genomics Research Institute. Stephan has founded or co-founded 14 biotechnology companies and advised many others. Stephan was co-founder of Navigenics, a personal genetics company.
David Berry is an American entrepreneur and business executive. He has co-founded Valo Health, Seres Therapeutics, Indigo Agriculture, Axcella Health, and contributed to the early development of Moderna.
Samir Mitragotri is an Indian American professor at Harvard University, an inventor, an entrepreneur, and a researcher in the fields of drug delivery and biomaterials. He is currently the Hiller Professor of Bioengineering and Hansjörg Wyss Professor of Biologically Inspired Engineering at Harvard John A. Paulson School of Engineering and Applied Sciences and the Wyss Institute for Biologically Inspired Engineering. Prior to 2017, he was the Duncan and Suzanne Mellichamp Chair Professor at University of California, Santa Barbara.
Brett P. Giroir is an American pediatrician. He was formerly the U.S. assistant secretary for health, a four-star admiral in the U.S. Public Health Service Commissioned Corps and an acting Food and Drug Administration commissioner.
Jeffrey Karp is a Canadian biomedical engineer working as a Professor of Medicine at Harvard Medical School, Brigham and Women's Hospital, and the principal faculty at the Harvard Stem Cell Institute and Affiliate Faculty at the Massachusetts Institute of Technology through the Harvard–MIT Division of Health Sciences and Technology. He is also an affiliate faculty at the Broad Institute.
David M. Sabatini is an American scientist and a former professor of biology at the Massachusetts Institute of Technology. From 2002 to 2021, he was a member of the Whitehead Institute for Biomedical Research. He was also an investigator of the Howard Hughes Medical Institute from 2008 to 2021 and was elected to the National Academy of Sciences in 2016. He is known for his contributions in the areas of cell signaling and cancer metabolism, most notably the co-discovery of mTOR.
Geoffrey von Maltzahn is an American biological engineer and businessman in the biotechnology and life sciences industry. Von Maltzahn has cofounded companies including Indigo Agriculture, Generate Biomedicines, Seres Therapeutics, Tessera Therapeutics, and Quotient Therapeutics.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer.
Gregory L. Verdine is an American chemical biologist, biotech entrepreneur, venture capitalist and university professor. He is a founder of the field of chemical biology, which deals with the application of chemical techniques to biological systems. His work has focused on mechanisms of DNA repair and cell penetrability.
Paul J. Tesar is an American developmental biologist. He is the Dr. Donald and Ruth Weber Goodman Professor of Innovative Therapeutics at Case Western Reserve University School of Medicine. His research is focused on regenerative medicine.
Kathryn Ann Whitehead is an American chemical engineer who is a professor at Carnegie Mellon University. Her research considers the development of nanomaterial-based drug delivery systems for gene therapy, oral macromolecular delivery systems, and maternal and infant therapeutics. She is an elected Fellow of the American Institute for Medical and Biological Engineering in 2021 and Fellow of the Controlled Release Society.
